ArticleAmerican journal of translational research2017
Effects of microRNA-29a on retinopathy of prematurity by targeting AGT in a mouse model.
Article in American journal of translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Epigenetics of Hypertensive Nephropathy.Biomedicines · 2024Review
- Epigenetic Regulation of the Renin-Angiotensin-Aldosterone System in Hypertension.International journal of molecular sciences · 2024Review
- Transcription factor c-fos induces the development of premature ovarian insufficiency by regulating MALAT1/miR-22-3p/STAT1 network.Journal of ovarian research · 2023Article
- Upregulated miR-194-5p suppresses retinal microvascular endothelial cell dysfunction and mitigates the symptoms of hypertensive retinopathy in mice by targeting SOX17 and VEGF signaling.Cell cycle (Georgetown, Tex.) · 2023Article
- Novel Potential Biomarkers for Retinopathy of Prematurity.Frontiers in medicine · 2022Review
- Expression profiles of long noncoding RNAs in retinopathy of prematurity.Neural regeneration research · 2020Article
- Osteopontin Upregulates Col IV Expression by Repressing miR-29a in Human Retinal Capillary Endothelial Cells.Molecular therapy. Nucleic acids · 2020Article
- Oxygen-induced circRNA profiles and coregulatory networks in a retinopathy of prematurity mouse model.Experimental and therapeutic medicine · 2019Article
- A therapeutic approach towards microRNA29 family in vascular diabetic complications: A boon or curse?Journal of diabetes and metabolic disorders · 2019Article
- Identifying circRNA-associated-ceRNA networks in retinal neovascularization in mice.International journal of medical sciences · 2019Article
- Animal Models of Diabetic Retinopathy.Current diabetes reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to explore the effects of microRNA-29a (miR-29a) on retinopathy of prematurity (ROP) by targeting angiotensinogen (AGT) expression in a mouse model.
methodsNinety-six C57BL/6J mice were selected and divided into the normal control group (n = 12) and the oxygen-induced retinopathy (OIR) group (n = 84). All the mice in the OIR group were assigned to the following seven groups (12 mice in each group): the blank, miR-29a mimics, miR-29a inhibitors, empty plasmid, miR-29a mimics + si-AGT, miR-29a inhibitors + si-AGT and si-AGT groups. ADPase histochemical staining was conducted to detect the morphology of retinal neovascularization. H&E staining was performed to quantify retinal neovascularization. The qRT-PCR assay was applied to detect the expression levels of miR-29a and the
resultsCompared with the normal control group, miR-29a expression decreased, while the
conclusionMiR-29a could inhibit retinal neovascularization to prevent the development and progression of ROP by down-regulating AGT.
Indexed as
Identifiers
28337307PMC5340714W2605626586What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.